GSK2140944
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has in…
Abstract Background Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits…
Abstract Background Uncomplicated urinary tract infections (uUTIs) are very common, with approximately 11% of women >18 years of…
Abstract Background At a urology center in Australia, patients undergoing elective nonurgent urological surgery routinely receive…
Abstract Background Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits…
ABSTRACT Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains…
Introduction Gepotidacin (GEP), a novel triazaacenaphthylene antibacterial, inhibits bacterial DNA replication. A Phase 2 study…
ABSTRACT Gepotidacin, a novel triazaacenaphthylene antibacterial agent, is the first in a new class of type IIA topoisomerase…
ABSTRACT GSK2140944 is a novel bacterial type II topoisomerase inhibitor with in vitro activity against key causative respiratory…
Several new antimicrobial candidate drugs that share enzyme targets with fluoroquinolones but act through distinct binding sites…